Evidence map›Paper›PMID 42835955›Full record

ArticleUrology case reports2026

From negative bone scintigraphy to oncologic superscan within five months: Explosive PSA kinetics in grade group 5 prostate adenocarcinoma.

Bartłomiej Olczak, Katarzyna Sklinda, Radoslaw Szostek, Marek Kasprowicz, Michał Małek, Łukasz Michałowski, Jerzy Walecki, Jan Bociański

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bartłomiej OlczakClinical Department of Urology and Oncological Urology, National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, Warsaw, 02-507, Poland.
Katarzyna SklindaCentre of Radiological Diagnostics, National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, Warsaw, 02-507, Poland.
Radoslaw SzostekClinical Department of Urology and Oncological Urology, National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, Warsaw, 02-507, Poland.
Marek KasprowiczClinical Department of Urology and Oncological Urology, National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, Warsaw, 02-507, Poland.
Michał MałekClinical Department of Urology and Oncological Urology, National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, Warsaw, 02-507, Poland.
Łukasz MichałowskiDepartment of Pathology, Medical University of Warsaw, Pawińskiego, Warsaw, 02-106, Poland.
Jerzy WaleckiCentre of Radiological Diagnostics, National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, Warsaw, 02-507, Poland.
Jan BociańskiCentre of Radiological Diagnostics, National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137, Warsaw, 02-507, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 78-year-old man presented with a prostate-specific antigen (PSA) level of 35 ng/mL, a PI-RADS 5 lesion on multiparametric prostate MRI, and negative whole-body bone scintigraphy. Within five months, PSA increased to 1244 ng/mL despite minimal radiological progression of the primary tumour. Repeat MRI demonstrated multiple osseous lesions, repeat MRI-ultrasound fusion-guided biopsy confirmed Grade Group 5 adenocarcinoma with cribriform architecture and perineural invasion, and repeat bone scintigraphy revealed an oncologic superscan consistent with high-volume metastatic disease. This case demonstrates that rapidly rising PSA levels accompanied by new skeletal symptoms should prompt immediate repeat staging despite initially negative whole-body bone scintigraphy.

Indexed as

Bone scintigraphyGrade group 5Prostate cancerProstate-specific antigenSkeletal metastasesSuperscan

Identifiers

PMID42835955
PMCPMC13636319

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.